Respiratory – Medxy AI

More Enteral Protein Did Not Overcome Anabolic Resistance in Mechanically Ventilated Critical Illness

By MedXY 05/13/2026

In a randomized trial, a 40 g intraduodenal whey bolus increased amino acid availability but did not significantly raise postprandial muscle protein synthesis versus 20 g in critically ill ventilated adults.

Critical Care news Respiratory

Predicted Body Weight May Be Too High for Many Critically Ill Women: New Evidence Challenges a Core Assumption in Lung-Protective Ventilation

By MedXY 05/12/2026

A large analysis suggests the predicted body weight equation overestimates lung size in critically ill women, increasing the risk of higher driving pressures and contributing to excess mortality under standard tidal-volume targeting.

Clinical Updates news Respiratory

Ivermectin for COVID-19: From Pandemic Controversy to Definitive Futility in the REMAP-CAP and Global Randomized Trials

By MedXY 05/12/2026

A comprehensive evidence-based synthesis of the REMAP-CAP trial and major international RCTs, demonstrating that ivermectin fails to improve clinical outcomes, survival, or organ support requirements in hospitalized and non-hospitalized COVID-19 patients.

Cardiology news Respiratory

A GOLD Science Committee Perspective on Exacerbations and Cardiovascular Risk In COPD

By MedXY 05/11/2026

COPD exacerbations significantly increase cardiovascular risk for months. This article examines the link between COPD and heart disease, emphasizing proactive screening during flare-ups and evidence-based prevention strategies to improve survival rates.

Critical Care news Respiratory

In-hospital influenza vaccination is associated with reduced 1-year mortality in critical patients with chronic pulmonary disease: a real world target trial emulation

By MedXY 05/09/2026

In critically ill chronic pulmonary disease patients, receiving influenza vaccination during hospitalization reduces 1-year mortality by 12%, lowers 90-day mortality by 12%, decreases readmission risk by 13%, and reduces emergency visits by 23%, with safety non-inferior to non-vaccinated patients.

Critical Care news Respiratory

Continuous Subphenotype Probabilities Expose High-Risk Patients Hidden Within “Hypoinflammatory” Acute Respiratory Failure

By MedXY 05/05/2026

AHRF patients classified as hypoinflammatory are not prognostically uniform. Continuous biomarker-based probabilities reveal substantial mortality heterogeneity, especially below the binary 0.5 threshold, with implications for enrichment strategies in phenotype-guided critical care trials.

Cardiology news Respiratory

Pulmonary Arterial Hypertension Therapy Preserves Gas Exchange Overall in Portopulmonary Hypertension, but New Intrapulmonary Vascular Dilatations Can Emerge

By MedXY 05/04/2026

In PoPH, PAH-specific therapy did not worsen oxygenation overall, although responses varied widely. Hemodynamic changes influenced gas exchange, and some patients developed new intrapulmonary vascular dilatations during follow-up.

Internal Medicine news Respiratory

Mild and Single Moderate COPD Exacerbations Predict Future Risks: Insights from a Community-Based Cohort Study

By MedXY 04/27/2026

Community-based COPD patients with mild or single moderate exacerbations show higher future exacerbation risks and lung structural abnormalities, despite stable lung function decline rates.

Neurology news Respiratory

Proximal Hypoglossal Nerve Stimulation Shows Promise for Moderate-to-Severe OSA in Landmark OSPREY Trial

By MedXY 04/24/2026

A recent randomized controlled trial demonstrates that proximal hypoglossal nerve stimulation significantly improves obstructive sleep apnea symptoms in patients intolerant to positive airway pressure therapy.

news Respiratory

Once-Daily Umeclidinium-Vilanterol Outperforms Other LAMA-LABA Combinations in Reducing COPD Exacerbations

By MedXY 04/13/2026

A large observational study finds that once-daily umeclidinium-vilanterol dry powder inhaler significantly reduces COPD exacerbation risk compared to glycopyrrolate-formoterol and tiotropium-olodaterol, while maintaining similar safety profiles across all three dual bronchodilator therapies.

Cardiology news Respiratory

Blood Eosinophil Count at COPD Exacerbation Predicts Long-Term Cardiovascular Risk: A Retrospective Cohort Study

By MedXY 04/11/2026

A large retrospective cohort study of 143,517 patients reveals that non-eosinophilic acute exacerbations of COPD carry a significantly higher one-year risk of major adverse cardiovascular events compared with eosinophilic exacerbations, suggesting blood eosinophil count as a potential biomarker for cardiovascular risk stratification in COPD.

Clinical Updates news Respiratory

Optimizing Positive End-Expiratory Pressure in Patients Without ARDS: From Non-Inferiority to Bayesian Probabilities of Benefit

By MedXY 04/03/2026

Bayesian re-analysis of the RELAx trial suggests a 75-78% probability that a lower PEEP strategy is superior to higher PEEP in ICU patients without ARDS, with even higher benefits observed in specific clinical subgroups.

Critical Care news Respiratory

Mortality Trends in Mechanically Ventilated ARDS: 20 Years of Paradox Revealed

By MedXY 04/02/2026

A landmark 20-year analysis of over 200,000 mechanically ventilated ARDS patients reveals a striking paradox—mortality declined during the ICD-9 era but increased after ICD-10 adoption, challenging assumptions about ARDS outcomes and highlighting the complex interplay between coding practices, patient complexity, and clinical care.

Internal Medicine news Respiratory

Nerandomilast in Idiopathic Pulmonary Fibrosis: Long-Term Insights from the FIBRONEER-IPF Trial

By MedXY 03/31/2026

An in-depth analysis of the FIBRONEER-IPF trial's extended follow-up data, evaluating the efficacy and safety of the PDE4B inhibitor nerandomilast in reducing clinical events and mortality in patients with idiopathic pulmonary fibrosis.

Internal Medicine news Respiratory

Nerandomilast Shows Potential Mortality Benefit in IPF Despite Neutral Composite Secondary Endpoints: Insights from FIBRONEER-IPF Extended Follow-up

By MedXY 03/28/2026

Long-term data from the FIBRONEER-IPF trial indicates that while nerandomilast did not significantly impact composite respiratory events, the 18 mg dose suggests a numerical reduction in mortality and maintains a favorable safety profile for patients with idiopathic pulmonary fibrosis.

Clinical Updates Diabetes & Endocrinology news Respiratory

Optimizing Influenza Protection in the Aging Diabetic Population: Evidence from the DANFLU-2 High-Dose Vaccine Trial

By MedXY 03/27/2026

This secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines provide superior protection against cardiorespiratory and cardiovascular hospitalizations in older adults with diabetes, particularly those with a disease duration exceeding five years.

Clinical Updates news Respiratory Transplantation

Post-Transplant Cyclophosphamide as a Potent Strategy for Bronchiolitis Obliterans Syndrome Prevention: A Comprehensive Clinical Synthesis

By MedXY 03/24/2026

This review evaluates the role of post-transplant cyclophosphamide (PTCy) in reducing the risk of bronchiolitis obliterans syndrome (BOS), highlighting recent multicenter data that demonstrates a 75% risk reduction mediated by the prevention of chronic graft-versus-host disease.

Infectious Diseases news Respiratory

Distinct Biological Pathways Drive Restrictive and Obstructive Post-Tuberculosis Lung Disease: Insights from a Kenyan Cohort

By MedXY 03/24/2026

A prospective Kenyan cohort study identifies that post-tuberculosis lung disease (PTLD) affects 50% of survivors, driven by divergent transcriptomic signatures: early pro-fibrotic inflammation in restrictive phenotypes and persistent interferon signaling in obstructive phenotypes.

news Otorhinolaryngology Respiratory

In-Lab vs. At-Home Sleep Studies: Determining Minimum Recording Time and the Role of Positional Sleep Apnea

By MedXY 03/23/2026

This study compares in-lab and home sleep tests, revealing that in-lab polysomnography requires at least 6 hours of recording for accuracy, while home tests need only 3 hours, particularly due to the variables introduced by positional obstructive sleep apnea.

news Oncology Respiratory

Beyond One-Size-Fits-All: Histologic Subtyping Redefines the Value of Lymph Node Dissection in Early Lung Adenocarcinoma

By MedXY 03/21/2026

A large-scale multicenter study reveals that guideline-adherent lymph node dissection provides a survival benefit only for patients with high-grade lung adenocarcinoma, suggesting that surgical extent should be tailored to histologic subtyping even in early-stage T1N0M0 disease.